First-in human, phase 1, dose-escalation pharmacokinetic and pharmacodynamic study of the oral dual PI3K and mTORC1/2 inhibitor PQR309 in patients with advanced solid tumors (SAKK 67/13)

Wicki Andreas; Brown Nicholas; Xyrafas Alexandros; Bize Vincent; Hawle Hanne; Berardi Simona; Cmiljanovic Natasa; Cmiljanovic Vladimir; Stumm Michael; Dimitrijevic Sasa; Herrmann Richard; Pretre Vincent; Ritschard Reto; Tzankov Alexandar; Hess Viviane; Childs Alexa; Hierro Cinta; Rodon Jordi; Hess Dagmar; Joerger Markus; von Moos Roger; Sessa Cristiana; Kristeleit Rebecca

首页> 外文期刊>European journal of cancer: official journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR) >First-in human, phase 1, dose-escalation pharmacokinetic and pharmacodynamic study of the oral dual PI3K and mTORC1/2 inhibitor PQR309 in patients with advanced solid tumors (SAKK 67/13)

【24h】

First-in human, phase 1, dose-escalation pharmacokinetic and pharmacodynamic study of the oral dual PI3K and mTORC1/2 inhibitor PQR309 in patients with advanced solid tumors (SAKK 67/13)

机译：先进实体肿瘤患者口服双PI3K和MTORC1 / 2抑制剂PQR309的首先人，第1期，剂量 - 升级药代动力学和药效学研究（SAKK 67/13）

获取原文

获取原文并翻译 | 示例

掌桥外文数据库（机构版） >>

开具论文收录证明 >>

文献代查 >>

页面导航

摘要
著录项
相似文献
相关主题

摘要

Background: PQR309 is an orally bioavailable, balanced panephosphatidylinositol-kinase (PI3K), mammalian target of rapamycin (mTOR) C1 and mTORC2 inhibitor.

机译：背景：PQR309是口服生物可利用的平衡的PANPOPHATIDYLIN肌醇激酶 - 激酶（PI3K），哺乳动物催盲蛋白（MTOR）C1和MTORC2抑制剂。

著录项

来源
《European journal of cancer: official journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)》 |2018年第2018期|共11页
作者
Wicki Andreas; Brown Nicholas; Xyrafas Alexandros; Bize Vincent; Hawle Hanne; Berardi Simona; Cmiljanovic Natasa; Cmiljanovic Vladimir; Stumm Michael; Dimitrijevic Sasa; Herrmann Richard; Pretre Vincent; Ritschard Reto; Tzankov Alexandar; Hess Viviane; Childs Alexa; Hierro Cinta; Rodon Jordi; Hess Dagmar; Joerger Markus; von Moos Roger; Sessa Cristiana; Kristeleit Rebecca;
展开▼
作者单位

Univ Hosp Basel Div Oncol Dept Biomed Petersgraben 4 CH-4031 Basel Switzerland;

Univ Coll London Hosp NHS Trust Gynecol Oncol Team 235 Euston Rd London NW1 2BU England;

SAKK Coordinating Ctr Effingerstr 33 CH-3008 Bern Switzerland;

SAKK Coordinating Ctr Effingerstr 33 CH-3008 Bern Switzerland;

SAKK Coordinating Ctr Effingerstr 33 CH-3008 Bern Switzerland;

SAKK Coordinating Ctr Effingerstr 33 CH-3008 Bern Switzerland;

Piqur Therapeut AG Hochbergstr 60C CH-4057 Basel Switzerland;

Piqur Therapeut AG Hochbergstr 60C CH-4057 Basel Switzerland;

Piqur Therapeut AG Hochbergstr 60C CH-4057 Basel Switzerland;

Piqur Therapeut AG Hochbergstr 60C CH-4057 Basel Switzerland;

Piqur Therapeut AG Hochbergstr 60C CH-4057 Basel Switzerland;

Univ Hosp Basel Dept Biomed Petersgraben 4 CH-4031 Basel Switzerland;

Univ Hosp Basel Dept Biomed Petersgraben 4 CH-4031 Basel Switzerland;

Univ Hosp Basel Dept Pathol Schonbeinstr 40 CH-4056 Basel Switzerland;

Univ Hosp Basel Div Oncol Dept Biomed Petersgraben 4 CH-4031 Basel Switzerland;

Univ Coll London Hosp NHS Trust Gynecol Oncol Team 235 Euston Rd London NW1 2BU England;

Univ Autonoma Barcelona Vall dHebron Inst Oncol Passeig Vall dHebron 119-129 Barcelona 08035;

Univ Autonoma Barcelona Vall dHebron Inst Oncol Passeig Vall dHebron 119-129 Barcelona 08035;

Cantonal Hosp St Gallen Dept Hematol &

Oncol Rorschacherstr 95 CH-9007 St Gallen Switzerland;

Cantonal Hosp St Gallen Dept Hematol &

Oncol Rorschacherstr 95 CH-9007 St Gallen Switzerland;

Cantonal Hosp Graubunden Dept Hematol &

Oncol Loestr 170 CH-7000 Chur Switzerland;

Osped San Giovanni Bellinzona Ist Oncol Svizzera Italiana CH-6500 Bellinzona Switzerland;

Univ Coll London Hosp NHS Trust Gynecol Oncol Team 235 Euston Rd London NW1 2BU England;

展开▼
收录信息
原文格式 PDF
正文语种 eng
中图分类肿瘤学;
关键词
PQR309; mTOR; PI3K; Phase 1; Solid tumours;

机译：PQR309;mtor;pi3k;阶段1;实体瘤;

相似文献

外文文献

1. First-in human, phase 1, dose-escalation pharmacokinetic and pharmacodynamic study of the oral dual PI3K and mTORC1/2 inhibitor PQR309 in patients with advanced solid tumors (SAKK 67/13) [J] . Wicki Andreas, Brown Nicholas, Xyrafas Alexandros, European journal of cancer: official journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR) . 2018,第期

机译：先进实体肿瘤患者口服双PI3K和MTORC1 / 2抑制剂PQR309的首先人，第1期，剂量 - 升级药代动力学和药效学研究（SAKK 67/13）
2. A Phase I Dose-Escalation Study to Assess Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of the Dual mTORC1/mTORC2 Kinase Inhibitor CC-223 in Patients With Advanced Solid Tumors or Multiple Myeloma [J] . Bendell Johanna C., Kelley Robin K., Shih Kent C., Cancer: A Journal of the American Cancer Society . 2015,第19期

机译：评估晚期实体瘤或多发性骨髓瘤患者双重mTORC1 / mTORC2激酶抑制剂CC-223的安全性，耐受性，药代动力学和初步疗效的I期剂量递增研究
3. 282 POSTER Preliminary results of a Phase I accelerated dose-escalation, pharmacokinetic and pharmacodynamic study of PF-03814735, an oral Aurora kinase A and B inhibitor, in patients with advanced solid tumors [J] . P.Sch?ffski, H.Dumez, S.F.Jones, European Journal of Cancer Supplements . 2008,第12期

机译：282 POSTER患有晚期实体瘤的患者的口服增强Aurora激酶A和B抑制剂PF-03814735的I期加速剂量递增，药代动力学和药效学研究的初步结果
4. Evaluation of the pharmacokinetic-pharmacodynamic relationship, metabolism and plasma protein binding of the novel antitumor agent, 2-methoxyestradiol (2ME2), following oral administration in patients with solid tumors. [D] . Lakhani, Nehal Jagdish. 2005

机译：实体瘤患者口服后评估新型抗肿瘤药2-甲氧基雌二醇（2ME2）的药代动力学与药效关系，代谢和血浆蛋白结合。
5. Phase I dose-escalation study of buparlisib (BKM120) an oral pan-class I PI3K inhibitor in Japanese patients with advanced solid tumors [O] . Yuichi Ando, Megumi Inada-Inoue, Ayako Mitsuma, 2014

机译：口服泛I类PI3K抑制剂buparlisib（BKM120）在日本患有晚期实体瘤的患者的I期剂量递增研究
6. Correction: Phase I Safety, Pharmacokinetic, and Pharmacodynamic Study of SAR245408 (XL147), an Oral Pan-Class I PI3K Inhibitor, in Patients with Advanced Solid Tumors [O] . 2015

机译：矫正：先进实体肿瘤患者的SAR245408（XL147）的I期安全性，药代动力学和药效学研究，口腔泛级I PI3K抑制剂

First-in human, phase 1, dose-escalation pharmacokinetic and pharmacodynamic study of the oral dual PI3K and mTORC1/2 inhibitor PQR309 in patients with advanced solid tumors (SAKK 67/13)

摘要

著录项

相似文献

相关主题

期刊订阅